Review proposes senotherapeutics as novel strategy for giant cell arteritis

A scientific review suggests that targeting cellular senescence with senolytics and senomorphics could address the age-related mechanisms driving persistent vascular injury in giant cell arteritis.

A scientific review published in Ageing Research Reviews examined the role of cellular senescence in giant cell arteritis (GCA), a large-vessel vasculitis that primarily affects individuals over the age of 50, with a peak incidence occurring between 70 and 80 years of age.

The authors reported that senescent smooth muscle cells, fibroblasts, endothelial cells, and immune cells accumulate in affected arteries and express a senescence-associated secretory phenotype (SASP), which releases pro-inflammatory cytokines, chemokines, and metalloproteinases.

The paper identified candidate senolytics (including fisetin, quercetin, curcumin, and dasatinib) and senomorphics (including resveratrol, rapamycin, metformin, and ruxolitinib) that could potentially modulate inflammatory and remodeling pathways, such as NF-κB, mTOR, and JAK/STAT, in GCA.

Current GCA therapies primarily suppress acute inflammation but do not address the underlying age-related mechanisms that lead to chronic vascular injury and tissue remodeling.

Targeting cellular senescence offers a potentially disease-modifying therapeutic approach to restore vascular immune balance and prevent pathological arterial remodeling.

Translational challenges remain, including the optimization of agent selection, dosing, and timing, as well as mitigating potential adverse vascular effects associated with certain senolytics.

The conceptual expansion of cellular senescence into large-vessel vasculitis suggests broader clinical pipeline opportunities for companies developing senolytics and senomorphics.

The theoretical validation of pathways like mTOR and JAK/STAT in GCA reinforces the therapeutic potential of longevity-focused immunometabolic platforms in autoimmune and vascular aging disorders.

Preclinical studies and translational models evaluating the efficacy and safety of specific senolytics and senomorphics in vascular tissues to support future clinical investigation in giant cell arteritis.